We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fusion Circular RNAs May Be Linked to Leukemia

By LabMedica International staff writers
Posted on 12 Apr 2016
Print article
Image: A bone marrow aspirate smear showing precursor B-cell acute lymphoblastic leukemia cells. Chromosomal translocations and gene fusions are common in various types of leukemia (Photo courtesy of Wikimedia Commons).
Image: A bone marrow aspirate smear showing precursor B-cell acute lymphoblastic leukemia cells. Chromosomal translocations and gene fusions are common in various types of leukemia (Photo courtesy of Wikimedia Commons).
The activity of noncoding circular RNAs has been linked to the development of leukemia and other cancers.

Chromosomal translocations result in the production of oncogenic fusion proteins that are involved in tumor formation. Whether such genomic alterations also affect noncoding RNAs is unclear, and their impact on circular RNAs (circRNAs) has not been rigorously examined.

Investigators at Beth Israel Deaconess Medical Center (Boston, MA, USA) reported in the March 31, 2016, online edition of the journal Cell that well-established cancer-associated chromosomal translocations gave rise to fusion circRNAs (f-circRNA) that were produced from transcribed exons of distinct genes affected by the translocations. F-circRNAs contributed to cellular transformation, promoted cell viability, and resistance upon therapy and had tumor-promoting properties in animal models.

As chromosomal translocations are common in various types of leukemia, the investigators examined acute promyelocytic leukemia cells, which often carry a translocation between the PML (Promyelocytic leukemia protein) and RAR-alpha (Retinoic acid receptor alpha) genes and acute myeloid leukemia cells, which can harbor a translocation between the MLL (Histone-lysine N-methyltransferase 2A) and AF9 (myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3) genes.

They found abnormal fusion-circular RNAs (f-circRNAs), corresponding to different exons associated with the PML-RAR-alpha gene fusion as well as the MLL-AF9 gene fusion.

Experiments were conducted in a mouse leukemia model that focused on a specific f-circRNA (f-circM9) associated with the MLL-AF9 fusion gene. Results indicated that the activity of f-circM9 in conjunction with other cancer-promoting signals could trigger the disease.

"Cancer is essentially a disease of mutated or broken genes, so that motivated us to examine whether circular RNAs, like proteins, can be affected by these chromosomal breaks," said senior author Dr. Pier Paolo Pandolfi, professor of medicine at Beth Israel Deaconess Medical Center. "These results are particularly exciting because they suggest that drugs directed at fusion-circular RNAs could be a powerful strategy to pursue for future therapeutic development in cancer. Our work paves the way to discovering many more of these unusual RNAs and how they contribute to cancer, which could reveal new mechanisms and druggable pathways involved in tumor progression."

Related Links:

Beth Israel Deaconess Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more